In Vivo Overexpression of IL-13 Receptor Alpha2 Chain Inhibits Tumorigenicity of Human Breast and Pancreatic Tumors in Immunodeficient Mice

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2001 Dec 19

PMID 11748276

Citations 23

Authors

K Kawakami

M Kawakami

P J Snoy

S R Husain

R K Puri

Affiliations

Soon will be listed here.

Abstract

Interleukin 13 receptor alpha2 (IL-13R(alpha)2) chain is highly expressed on some tumor cell lines and primary cell cultures. This receptor chain plays an important role in ligand binding and internalization. To determine the functional significance of overexpression of this chain, we stably transfected IL-13R(alpha)2 chain in human breast (MDA-MB-231) and pancreatic (PANC-1) cancer cell lines that naturally do not express this chain. There was no difference in growth between vector only transfected and IL-13R(alpha)2 chain transfected cells in vitro. However, surprisingly, in immunodeficient mice, tumorigenicity was profoundly inhibited in IL-13R(alpha)2 chain overexpressing tumors. Because breast tumors that grew later showed loss of IL-13R(alpha)2 gene expression, lack of tumorigenicity correlated positively with IL-13R(alpha)2 chain expression. Inflammatory cells including neutrophils and macrophages were identified in IL-13R(alpha)2 overexpressing regressing tumors and neutrophils were found to produce IL-13. IL-13 showed a modest antitumor activity to IL-13R(alpha)2 chain overexpressing tumors in vitro and in vivo. Furthermore, IL-13R(alpha)2 chain overexpressing tumors constitutively produced IL-8 that has been shown to have antitumor effect. These results establish a novel function of a cytokine receptor chain and further suggest that the presence of this chain on tumor cells by itself may play a key role in tumorigenicity.

Citing Articles

Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.

Kashyap D, Salman H Int J Mol Sci. 2024; 25(7).

PMID: 38612592 PMC: 11011362. DOI: 10.3390/ijms25073780.

A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL-13Rα2-mediated JNK-AP-1 signals.

Lee Y, Yu J, Kim K, Lee D, Son D, Lee H Mol Oncol. 2021; 16(2):508-526.

PMID: 34758182 PMC: 8763653. DOI: 10.1002/1878-0261.13138.

IL13Rα2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases.

Marquez-Ortiz R, Contreras-Zarate M, Tesic V, Alvarez-Eraso K, Kwak G, Littrell Z Clin Cancer Res. 2021; 27(22):6209-6221.

PMID: 34544797 PMC: 8595859. DOI: 10.1158/1078-0432.CCR-21-0361.

Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer.

Shi J, Song X, Traub B, Luxenhofer M, Kornmann M Int J Mol Sci. 2021; 22(6).

PMID: 33804263 PMC: 8000536. DOI: 10.3390/ijms22062998.

Loss of 5'-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness.

de Menezes W, Silva V, Gomes I, Rosa M, Spina M, Carloni A Cells. 2020; 9(2).

PMID: 32093414 PMC: 7072758. DOI: 10.3390/cells9020492.

References

Inoue K, Slaton J, Eve B, Kim S, Perrotte P, Balbay M . Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000; 6(5):2104-19. View

Mantovani A . The chemokine system: redundancy for robust outputs. Immunol Today. 1999; 20(6):254-7. DOI: 10.1016/s0167-5699(99)01469-3. View

Kawakami K, Leland P, Puri R . Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res. 2000; 60(11):2981-7. View

Brandt E, Woerly G, Younes A, Loiseau S, Capron M . IL-4 production by human polymorphonuclear neutrophils. J Leukoc Biol. 2000; 68(1):125-30. View

Weinstein E, Leder P . The extracellular region of heregulin is sufficient to promote mammary gland proliferation and tumorigenesis but not apoptosis. Cancer Res. 2000; 60(14):3856-61. View

Liu H, Jacobs B, Liu J, Prayson R, Estes M, Barnett G . Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol Immunother. 2000; 49(6):319-24. PMC: 11036967. DOI: 10.1007/s002620000110. View

Kawakami K, Joshi B, Puri R . Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain. Hum Gene Ther. 2000; 11(13):1829-35. DOI: 10.1089/10430340050129459. View

Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S . Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 2000; 6(9):3530-5. View

Rennert P, Schneider P, Cachero T, Thompson J, Trabach L, Hertig S . A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med. 2000; 192(11):1677-84. PMC: 2193103. DOI: 10.1084/jem.192.11.1677. View

10.

Ameixa C, Friedland J . Down-regulation of interleukin-8 secretion from Mycobacterium tuberculosis-infected monocytes by interleukin-4 and -10 but not by interleukin-13. Infect Immun. 2001; 69(4):2470-6. PMC: 98181. DOI: 10.1128/IAI.69.4.2470-2476.2001. View

11.

Kawakami K, Taguchi J, Murata T, Puri R . The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood. 2001; 97(9):2673-9. DOI: 10.1182/blood.v97.9.2673. View

12.

Yamashiro S, Kamohara H, Wang J, Yang D, Gong W, Yoshimura T . Phenotypic and functional change of cytokine-activated neutrophils: inflammatory neutrophils are heterogeneous and enhance adaptive immune responses. J Leukoc Biol. 2001; 69(5):698-704. View

13.

Kawakami K, Takeshita F, Puri R . Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor alpha 2 chain. J Biol Chem. 2001; 276(27):25114-20. DOI: 10.1074/jbc.M100936200. View

14.

Kawakami K, Kawakami M, Joshi B, Puri R . Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 2001; 61(16):6194-200. View

15.

Kawakami K, Husain S, Bright R, Puri R . Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther. 2002; 8(11):861-8. DOI: 10.1038/sj.cgt.7700373. View

16.

Munson P, Rodbard D . Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980; 107(1):220-39. DOI: 10.1016/0003-2697(80)90515-1. View

17.

Brown K, Zurawski S, Mosmann T, Zurawski G . A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol. 1989; 142(2):679-87. View

18.

Tepper R, Pattengale P, Leder P . Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989; 57(3):503-12. DOI: 10.1016/0092-8674(89)90925-2. View

19.

Puri R, Ogata M, Leland P, FELDMAN G, Fitzgerald D, Pastan I . Expression of high-affinity interleukin 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin. Cancer Res. 1991; 51(11):3011-7. View

20.

Tepper R, Coffman R, Leder P . An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science. 1992; 257(5069):548-51. DOI: 10.1126/science.1636093. View